Company intelligence / Profile preview
Vergent Bioscience
Minneapolis, Minnesota, United Statesvergentbio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Currently sponsoring a Phase 2b multi-center study evaluating abenacianine for injection (VGT-309) in surgery for cancer in the lung at leading hospitals in the U.S. and Australia. Recent Phase 2 data showed VGT-309 visualizes tumors in the lung during surgery (as of June 3, 2024)[4].
- Therapeutic areas
- Oncology
- Modalities
- Fluorescent imaging agentsTumor-targeted agents
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Intuitive (investor)
Beyond the preview
Go deeper on Vergent Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vergent Bioscience.